

5 August 2014

## 2014/15 Invitation to Tender

PHARMAC is seeking feedback from medical groups, DHB hospital pharmacies and other interested parties on:

- A proposal to tender certain pharmaceuticals for sole supply; and
- The draft process and terms and conditions for the 2014/15 Invitation to Tender (2014/15 Tender).

PHARMAC welcomes all feedback on the 2014/15 Tender. Feedback received by the deadline may be considered by the Tender Medical Evaluation Subcommittee of PTAC, and would be considered by the PHARMAC Board (or its Delegate) prior to making a decision on this proposal.

**ALL RESPONSES ARE DUE BY 5PM, THURSDAY 4 SEPTEMBER 2014**

Feedback should be provided by submitting an email, fax or letter to the Tender Analysts:

Email: [tender@pharmac.govt.nz](mailto:tender@pharmac.govt.nz)

Letter: Tender Analyst  
PHARMAC  
PO Box 10-254  
Wellington 6143

Fax: (04) 460 4995

DDI: Chloe Dimock: (04) 916 7263  
Laurence Holding: (04) 901 2844

Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.

We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.

## **Details of the proposed 2014/15 Tender**

In accordance with PHARMAC's objective (to secure, for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided), PHARMAC is consulting on a proposal to tender certain pharmaceuticals for Sole Subsidised Supply to community pharmacies and/or Hospital Supply Status for supply to DHB hospital pharmacies.

Attached to this letter (as Schedule Two) is a list of pharmaceuticals that we are considering tendering for Sole Subsidised Supply and/or Hospital Supply Status. Pharmaceuticals are sorted into therapeutic groups and then listed alphabetically in each group by chemical, form and strength. Each pharmaceutical has a 'C' and/or 'H' next to it to indicate whether it is proposed to be tendered for community and/or hospital supply.

In general, the proposed Tender process would be similar to the 2013/14 Tender. A copy of the draft 2014/15 Invitation to Tender is available on our website: [www.pharmac.health.nz](http://www.pharmac.health.nz), or by contacting PHARMAC.

We are seeking feedback on the approach outlined in the following pages, in particular on:

- The proposed tender process and timeline;
- The actual or potential clinical implications of awarding Sole Subsidised Supply and/or Hospital Supply Status to the pharmaceuticals listed in Schedule Two, including the impact of a brand switch on patients and clinical staff; and
- For hospital pharmaceuticals, your views on the appropriate Discretionary Variance (DV) Limit for each pharmaceutical, in the event you consider a 1% DV Limit to be clinically unacceptable.

## **Background**

Since 1997 PHARMAC has been using the strategy of tendering pharmaceuticals for sole supply of pharmaceuticals for a fixed period of time. Regular tendering has proven to be an effective way to encourage competition among suppliers of pharmaceuticals. As in the past, the community and hospital tender processes would be run in unison, however, the pharmaceutical list for community and hospital supply may be different.

## **Key Aspects of Awarding a Tender for Community Pharmaceuticals:**

- For community pharmaceuticals, the tender winning brand would be the only subsidised brand for up to approximately 3 years. The Sole Subsidised Supply period would conclude on 30 June 2018 for all Tenders awarded from the 2014/15 Tender.
- No other brand of the pharmaceutical would be listed (or subsidised) in Section B of the Pharmaceutical Schedule during the Sole Subsidised Supply period.
- Other brands could continue to be marketed, sold and dispensed during the Sole Subsidised Supply Status period, but they would not receive a subsidy.
- Any pharmaceutical that currently carries a manufacturer's surcharge (that is, the additional patient charge above that of the patient co-payment) would become fully subsidised if a tender was awarded for that pharmaceutical.

### Key Aspects of Awarding a Tender for DHB Hospital Pharmaceuticals:

- For DHB hospital pharmaceuticals, the Hospital Supply Status brand would be the only brand DHB Hospitals could purchase (subject to any allowance for alternative brands under the agreed DV Limits) for up to approximately 3 years. The Hospital Supply Status period would conclude on 30 June 2018 for all tenders awarded from the 2014/15 Tender.
- No other brand of the pharmaceutical would be listed in Section H of the Pharmaceutical Schedule during the Hospital Supply Status period.

### Tender Timelines

The proposed timelines for the 2014/15 Tender are as follows:

Date	Event
5 August 2014	Consultation with suppliers, medical groups and interested parties on the proposed pharmaceutical list and draft Invitation to Tender.
28 August 2014	Final date for receipt of Alternative Commercial Proposals (ACPs) to tendering by PHARMAC.
4 September 2014	Final date for all consultation to be received.
September 2014	PHARMAC considers feedback from consultation, negotiates with suppliers over any ACP proposals it considers would meet PHARMAC's Decision Criteria and enters into provisional contracts with suppliers where appropriate.
September 2014	Meeting of the Tender Medical Evaluation Subcommittee of PTAC to consider clinical issues in relation to the proposed Tender list.
September/October 2014	Consultation and Board decisions on Alternative Commercial Proposals.
Early November 2014	Issuing of the 2014/15 Tender.
18 December 2014	Invitation to Tender closes.
From end of January 2015	Board decisions on the first Tender winners announced.

### Contractual obligations for suppliers

A copy of the draft terms and conditions which would form the terms of the 2014/15 Tender contract is available on the PHARMAC website: [www.pharmac.health.nz](http://www.pharmac.health.nz), or by phoning PHARMAC on 0800 66 00 50.

### Unresolved Tender Bids

PHARMAC would review any unresolved Tender Bids from 2012/13 Tender and the 2013/14 Tender prior to issuing the 2014/15 Tender, and may close the tender for some of these items, and reissue them as part of the 2014/15 tender. The following Tender Bids remain unresolved, and may potentially be added to the 2014/15 Tender following consultation:

*2012/13 Invitation to Tender*

Chemical Name	Line Item
Clobetasol Propionate	Crm 0.05% (pack size 30 g or less)
Clobetasol Propionate	Oint 0.05% (pack size 30 g or less)
Dorzolamide hydrochloride with timolol maleate	Eye drops 2% with timolol maleate 0.5%
Escitalopram	Tab 10 mg
Escitalopram	Tab 20 mg
Latanoprost with timolol	Eye drops 50 mcg per ml with timolol 0.5%
Minocycline Hydrochloride	Tab 50 mg
Oestradiol	TDDS 25 mcg per day
Oestradiol	TDDS 50 mcg per day
Oestradiol	TDDS 75 mcg per day
Oestradiol	TDDS 100 mcg per day
Phenoxymethylpenicillin (Penicillin V)	Cap 250 mg
Phenoxymethylpenicillin (Penicillin V)	Cap 500 mg
Sodium Cromoglycate	Eye drops 2%
Tranexamic Acid	Inj 100 mg per ml, 5 ml - 10 ml
Ziprasidone	Cap 80 mg
Ziprasidone	Cap 20 mg
Ziprasidone	Cap 40 mg
Ziprasidone	Cap 60 mg

*2013/14 Invitation to Tender*

Chemical Name	Line Item
Aciclovir	Eye oint 3%
Allopurinol	Tab 100 mg
Allopurinol	Tab 300 mg
Amlodipine	Tab 5 mg
Amlodipine	Tab 10 mg
Amlodipine	Tab 2.5 mg
Aqueous Cream	Crm (greater than 100 g)
Aqueous Cream	Crm (100 g or less)
Aripiprazole	Tab 10 mg
Aripiprazole	Tab 15 mg
Aripiprazole	Tab 20 mg
Aripiprazole	Tab 30 mg
Artesunate	Inj 60 mg
Bisoprolol Fumarate	Tab 2.5 mg
Bisoprolol Fumarate	Tab 5 mg
Bisoprolol Fumarate	Tab 10 mg
Brinzolamide	Eye Drops 1%
Calcium folinate	Tab 15 mg
Carvedilol	Tab 6.25 mg

Chemical Name	Line Item
Carvedilol	Tab 12.5 mg
Carvedilol	Tab 25 mg
Celecoxib	Cap 100 mg
Celecoxib	Cap 200 mg
Cetirizine hydrochloride	Tab 10 mg
Chlorhexidine gluconate	Soln 4%
Cidofovir	Inj 75 mg per ml, 5 ml
Ciprofloxacin	Eye Drops 0.3%
Cisplatin	Inj 1 mg per ml, 100 ml
Cisplatin	Inj 1 mg per ml, 50 ml
Citalopram hydrobromide	Tab 20 mg
Clarithromycin	Inj 500 mg
Clofazimine	Cap 50 mg
Clofazimine	Cap 50 mg
Clonazepam	Tab 2 mg
Clonazepam	Tab 500 mcg
Cyclophosphamide	Tab 50 mg
Cyclophosphamide	Inj 2 g
Cyclophosphamide	Inj 1 g

Chemical Name	Line Item
Dipyridamole	Tab long-acting 150 mg
Donepezil hydrochloride	Tab 5 mg
Donepezil hydrochloride	Tab 10 mg
Emulsifying ointment	Oint BP (pack size 200 g or less)
Emulsifying ointment	Oint BP (pack size greater than 200 g)
Ephedrine	Inj 30 mg per ml, 1ml
Esomeprazole	Inj 40 mg
Etoricoxib	Tab 60 mg
Etoricoxib	Tab 90 mg
Etoricoxib	Tab 120 mg
Ezetimibe	Tab 10 mg
Ezetimibe with simvastatin	Tab 10 mg with simvastatin 20 mg
Ezetimibe with simvastatin	Tab 10 mg with simvastatin 40 mg
Ezetimibe with simvastatin	Tab 10 mg with simvastatin 80 mg
Ezetimibe with simvastatin	Tab 10 mg with simvastatin 10 mg
Fludarabine phosphate	Inj 50 mg
Fluorouracil sodium	Inj 50 mg per ml, 20 ml
Fluorouracil sodium	Inj 50 mg per ml, 50 ml
Fluorouracil sodium	Inj 50 mg per ml, 10 ml
Fluorouracil sodium	Inj 50 mg per ml, 100 ml
Hydrocortisone	Crn 1% (pack size greater than 15 g and less than 100 g)
Hydrocortisone	Crn 1% (pack size greater than 100 g)
Hyoscine N-butylbromide	Tab 10 mg
Imipenem with cilastatin	Inj 500 mg with cilastatin 500 mg
Ketamine	Inj 100 mg per ml, 2 ml vial
Lice treatment	lotn
Lice treatment	Shampoo
Mebendazole	Tab 100 mg
Mefenamic acid	Cap 250 mg
Meloxicam [current access]	Tab 7.5 mg
Meloxicam [widened access]	Tab 7.5 mg
Metronidazole	Inj 5 mg per ml, 100ml
Mitozantrone	Inj 2 mg per ml, 10 ml
Mitozantrone	Inj 2 mg per ml, 12.5 ml
Morphine sulphate	Tab immediate release 10 mg
Morphine sulphate	Tab immediate release 20

Chemical Name	Line Item
	mg
Nitazoxanide	Oral liquid 100mg per 5ml
Norethisterone	Tab 5 mg
Nystatin	Oral liq 100,000 u per ml
Omeprazole	Cap 10 mg
Omeprazole	Cap 20 mg
Omeprazole	Cap 40 mg
Omeprazole	Inj 40 mg
Omeprazole	Inf 40 mg
Omeprazole	Powder
Ornidazole	Tab 500 mg
Oxybuprocaine hydrochloride	Eye drops 0.4%, single dose
Paracetamol	Tab soluble 500 mg
Permethrin	Crn 5%
Pregnancy tests - hCG urine	Urine diagnostic test
Propofol	Inj 10 mg per ml, 20 ml vial
Propofol	Inj 10 mg per ml, 20 ml ampoule
Propofol	Inj 10 mg per ml, 50 ml vial
Propofol	Inj 10 mg per ml, 100 ml vial
Risperidone	Orally-disintegrating tablets 0.5 mg
Risperidone	Orally-disintegrating tablets 1 mg
Risperidone	Orally-disintegrating tablets 2 mg
Ropivacaine hydrochloride	Inj 2 mg per ml, 10 ml
Ropivacaine hydrochloride	Inj 2 mg per ml, 20 ml
Ropivacaine hydrochloride	Inj 2 mg per ml, 100 ml
Ropivacaine hydrochloride	Inj 2 mg per ml, 200 ml
Ropivacaine hydrochloride	Inj 7.5 mg per ml, 10 ml
Ropivacaine hydrochloride	Inj 7.5 mg per ml, 20 ml
Ropivacaine hydrochloride	Inj 10 mg per ml, 10 ml
Ropivacaine hydrochloride	Inj 10 mg per ml, 20 ml
Sodium chloride	Inj 0.9%, 5 ml
Sodium chloride	Inj 0.9%, 10 ml
Sodium chloride	Inj 0.9%, 20 ml
Sodium chloride	Soln 0.9% for irrigation, 30 ml
Sodium Citro-Tartrate	Grans effervescent 4 g sachets
Sodium hyaluronate	Inj 23 mg per ml, 0.6ml syringe
Sodium hyaluronate with chondroitin sulphate	Inj 30 mg with chondroitin sulphate 40mg per ml,

Chemical Name	Line Item
	0.75ml syringe
Spiramycin	Tab 500 mg
Thiopental [Thiopentone] sodium	Inj 500 mg
Tobramycin	Inj 40 mg per ml, 2 ml
Travoprost	Eye drops 0.004%
Triamcinolone acetonide	Inj 10 mg per ml, 1 ml
Triamcinolone acetonide	Inj 40 mg per ml, 1 ml
Triamcinolone acetonide	0.1% in Dental Paste USP
Triamcinolone acetonide	Crn 0.02%
Triamcinolone acetonide	Oint 0.02%
Water for Injection	Purified for inj 5 ml
Water for Injection	Purified for inj 10 ml
Water for Injection	Purified for inj 20 ml
Wool fat	Crn
Zinc	Crn BP
Zinc	Oint BP
Zinc and castor Oil	Oint BP (pack size 30 g or less)
Zinc and castor Oil	Oint BP (pack size greater than 30 g)
Zinc sulphate	Cap 50 mg elemental

Should any unresolved Tender Bids be declined, PHARMAC would consider including those pharmaceuticals in the 2014/15 Tender. Currently unresolved Tender Bids have not been included in the draft pharmaceutical list set out in Schedule Two.

### **Distribution of Consultation Documents**

Although this consultation letter has been widely distributed, should you consider that a particular person, group or agency should receive this letter and/or future tender documents, please feel free to contact PHARMAC or refer it on directly (note, all tender documents and consultations are also available from our website at [www.pharmac.health.nz/news#consultation](http://www.pharmac.health.nz/news#consultation)). We also invite any person or group to contact PHARMAC should you wish to meet to discuss the proposals contained in this consultation letter.

### **ScheduleTwo: Possible pharmaceuticals for tender for sole supply**

#### **Order of pharmaceuticals in this Schedule**

Pharmaceuticals have been listed in groups according to the therapeutic group classification system used in the Pharmaceutical Schedule. Below is a list of these groups, and the corresponding page numbers for your ease of reference. Pharmaceuticals with indications that may apply to multiple therapeutic groups will only appear in one group.

<b><i>Therapeutic Group</i></b>	<b>Page Numbers</b>
Alimentary Tract and Metabolism	9 – 10
Blood and Blood Forming Organs	10 – 12
Cardiovascular System	12 – 14
Dermatologicals	14 – 16
Genito-Urinary System	16
Hormone Preparations – Systemic excluding contraceptives	17
Infections – Agents for Systemic Use	17 – 21
Musculoskeletal System	21 – 22
Nervous System	22 – 25
Oncology and Immunosuppressants	25 – 27
Respiratory System and Allergies	27
Sensory Organs	27 – 28
Various	28 – 30

#### **Information provided for each pharmaceutical**

For each pharmaceutical (as defined by chemical name, form and strength) we have provided the following information:

- the current ex-manufacturer subsidy per unit of measure as at 1 July 2014
- the number of subsidised or partially subsidised units sold in the community in the year ending 30 June 2014
- an estimate of the annual community market value at current subsidies (estimated by multiplying the volume of units subsidised in the year ending 30 June 2014 by the relevant listed unit subsidy as at 1 July 2014); and

- comments specifically relating to the Tender of the line item and/or its current listing on the Pharmaceutical Schedule.

### Explanation of terms, symbols and abbreviations

Most terms and abbreviations used are self explanatory: “tab” means tablet, “cap” means capsule, “liq” means liquid, “inj” means injection, “suppos” means suppository, “grans” mean granules and “OP” means original pack to be dispensed.

The following table explains the symbols used in the draft pharmaceutical list:

Symbol	Explanation
Underlined	Pharmaceutical line items where a sole supply contract is in force are underlined. The price and subsidy for these pharmaceuticals are fixed until 30 June 2015 unless otherwise stated in the Comments column and a listing of a new brand could only occur after that date.
C	To be tendered for Sole Subsidised Supply Status (community pharmaceuticals).
H	To be tendered for Hospital Supply Status (DHB hospital pharmaceuticals).
PCT	A reference in the Invitation to Tender to allow Pharmaceuticals Cancer Treatments to be listed in Section B of the Pharmaceutical Schedule as part of PHARMAC’s Pharmaceutical Cancer Treatments project.
+	PHARMAC has been advised of the existence of a patent.
*	There is no fully funded product available for this line item (in relation to community supply).
@	Additional Stock Pharmaceuticals (ASP) means a Pharmaceutical, marked with an “@”, for which the supplier of the successful Tender Bid would be required to hold additional stock.
#	A rebate currently exists.

### Medical Devices- IV infusion bags

Following discussions with a number of hospital pharmacists, PHARMAC has included a variety of empty IV infusion bags in the draft 2014/15 Invitation to Tender. PHARMAC would welcome specific feedback on the appropriateness of tendering these products, the suitability of the proposed line items, and the variety of proposed products.



**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Alimentary Tract and Metabolism**

<b>Chemical Name</b>							
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>	
<b>Acarbose</b>							
<u>Tab 50 mg</u>	1,923,281	\$209,849	\$0.1091		C H 1%		
<u>Tab 100 mg</u>	1,143,688	\$201,163	\$0.1759		C H 1%		
<b>Atropine sulphate</b>							
<u>Inj 600 mcg, 1 ml</u>	52,020	\$73,868	\$1.4200		C H 1%		
<b>Bisacodyl</b>							
Tab 5 mg	1,488,985	\$37,150	\$0.0250		C H 1%		
<b>Chlorhexidine gluconate</b>							
<u>Mouthwash 0.2%</u>	4,262,200	\$57,113	\$0.0134		C H 1%		
<b>Cimetidine</b>							
Tab 200 mg	49,720	\$2,486	\$0.0500	*	C H 1%		
Tab 400 mg	168,074	\$16,807	\$0.1000	*	C H 1%		
Tab 800 mg					C H 1%	Not currently listed on the Pharmaceutical Schedule	
<b>Colecalciferol</b>							
Oral liquid (400 – 1,000 iu per ml)					C H 1%	Not currently listed on the Pharmaceutical Schedule. Any agreement may be subject to restrictions. PHARMAC may award a tender for one or a combination of Vitamin D products	
Tab (1,000 iu)					C H 1%	Not currently listed on the Pharmaceutical Schedule. Any agreement may be subject to restrictions. PHARMAC may award a tender for one or a combination of Vitamin D products	
Tab 1.25 mg (50,000 iu)	2,482,481	\$1,605,346	\$0.6467		C H 1%	PHARMAC may award a tender for one or a combination of Vitamin D products	
<b>Docosate Sodium with Sennosides</b>							
Tab 50 mg with total sennosides 8 mg	42,369,829	\$1,351,598	\$0.0319		C H 1%		
<b>Famotidine</b>							
Tab 20 mg					C H 1%	Not currently listed on the Pharmaceutical Schedule	
Tab 40 mg					C H 1%	Not currently listed on the Pharmaceutical Schedule	
<b>Ferrous Fumarate</b>							
Tab 200 mg	16,656,300	\$724,549	\$0.0435		C H 1%		
<b>Glipizide</b>							
<u>Tab 5 mg</u>	14,786,738	\$443,602	\$0.0300		C H 1%		
<b>Glycerol</b>							
<u>Suppos greater than 3 g</u>	286,867	\$93,232	\$0.3250		C H 1%		
<b>Hydrocortisone Acetate</b>							
<u>Rectal foam 10%, CFC-free</u>	211,865	\$254,037	\$1.1991		C H 1%		
<b>Hydroxocobalamin</b>							
<u>Inj 1 mg per ml, 1 ml</u>	283,513	\$481,972	\$1.7000		C H 1%		
<b>Hyoscine N-butylbromide</b>							
Inj 20 mg, 1 ml	107,581	\$205,910	\$1.9140		C H 1%		
<b>Iron sucrose</b>							
Inj 20 mg per ml, 5 ml ampoule					H 1%		
<b>Lansoprazole</b>							
<u>Cap 15 mg</u>	1,375,337	\$98,240	\$0.0714		C H 1%		
<u>Cap 30 mg</u>	3,552,505	\$294,361	\$0.0829		C H 1%		
<b>Magnesium</b>							
Tab					C H 1%	Not currently listed on the Pharmaceutical Schedule. Any agreement may be subject to Special Authority restriction. All salt formulations will be considered. Products would require the mmol content of magnesium to be stated on the label	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Alimentary Tract and Metabolism**

<b>Chemical Name</b>						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
<b>Mesalazine</b>						
<u>Enema 1 g per 100 ml</u>	55,414	\$349,267	\$6.3029	C H	1%	
Suppos 500 mg	122,113	\$139,209	\$1.1400	C H	1%	
Suppos 1 g	151,518	\$275,763	\$1.8200	C H	1%	
<b>Metformin Hydrochloride</b>						
<u>Tab immediate-release 500 mg</u>	114,008,798	\$1,402,308	\$0.0123	C H	1%	
<u>Tab immediate-release 850 mg</u>	16,727,985	\$337,905	\$0.0202	C H	1%	
<b>Miconazole</b>						
<u>Oral gel 20 mg per g</u>	482,840	\$59,751	\$0.1238	C H	1%	
<b>Pancreatic enzyme</b>						
Cap EC 20,000-25,000 BP u lipase, 12,000-18,000 BP u amylase and 900-1,100 BP u protease	1,997,279	\$1,885,032	\$0.9438	C H	1%	
Cap EC 24,000-25,000 BP u lipase, 22,000-23,000 BP u amylase and 1,000-1,500 BP u protease	50,458	\$47,632	\$0.9440	C H	1%	
Cap EC 9,000 -11,000BP u lipase, 8,000-10,000 BP u amylase and 150-500 BP u protease	1,988,278	\$694,506	\$0.3493	C H	1%	
Powder				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule
<b>Pantoprazole</b>						
Inj 40 mg				H	1%	
<b>Pioglitazone</b>						
<u>Tab 15 mg</u>	462,759	\$24,790	\$0.0536	C H	1%	
<u>Tab 30 mg</u>	398,697	\$35,600	\$0.0893	C H	1%	
<u>Tab 45 mg</u>	306,401	\$38,300	\$0.1250	C H	1%	

**Blood and Blood Forming Organs**

<b>Chemical Name</b>						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
<b>Alteplase</b>						
Inj 10 mg				H	1%	
Inj 50 mg				H	1%	
<b>Aprotinin</b>						
Inj 10,000,000 iu per ml, 50 ml				H	1%	
<b>Dalteparin Sodium</b>						
Inj 10,000 iu per ml, 1 ml	375	\$2,908	\$7.7550	C H	1%	Delisting and/or subsidy reduction and/or price protection until 1/07/2015
Inj 12,500 iu per ml, 0.5 ml	210	\$2,099	\$9.9960	C H	1%	Delisting and/or subsidy reduction and/or price protection until 1/07/2015
Inj 15,000 iu per ml, 0.6 ml	370	\$4,442	\$12.0050	C H	1%	Delisting and/or subsidy reduction and/or price protection until 1/07/2015
Inj 18,000 iu per ml, 0.72 ml	340	\$5,388	\$15.8470	C H	1%	Delisting and/or subsidy reduction and/or price protection until 1/07/2015
Inj 2,500 iu per ml, 0.2 ml	554	\$1,106	\$1.9970	C H	1%	Delisting and/or subsidy reduction and/or price protection until 1/07/2015
Inj 5,000 iu per ml, 0.2 ml	434	\$1,733	\$3.9940	C H	1%	Delisting and/or subsidy reduction and/or price protection until 1/07/2015
Inj 7,500 iu per ml, 0.75 ml			\$6.0030	C H	1%	Delisting and/or subsidy reduction and/or price protection until 1/07/2015
<b>Danaparoid</b>						
Inj 750 u in 0.6ml ampoule				H	1%	
<b>Defibrotide</b>						
Inj 200 mg				H	1%	Not currently listed on the Pharmaceutical Schedule

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Blood and Blood Forming Organs**

<b>Chemical Name</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>DV Limit</b>	<b>Comments</b>
<b>Dextrose with sodium citrate and citric acid</b>					
Inj 24.5 mg with sodium citrate 22 mg and citric acid 7.3 mg per ml, 100 ml bag				H 1%	
<b>Enoxaparin sodium</b>					
<u>Inj 20 mg per 0.2 ml</u>	12,930	\$48,151	\$3.7240	C H 1%	Access may be widened and/or SA restrictions removed depending on pricing received
<u>Inj 40 mg per 0.4 ml</u>	133,125	\$661,496	\$4.9690	C H 1%	Access may be widened and/or SA restrictions removed depending on pricing received.
<u>Inj 60 mg per 0.6 ml</u>	51,928	\$388,993	\$7.4910	C H 1%	Access may be widened and/or SA restrictions removed depending on pricing received
<u>Inj 80 mg per 0.8 ml</u>	79,827	\$797,152	\$9.9860	C H 1%	Access may be widened and/or SA restrictions removed depending on pricing received
<u>Inj 100 mg per ml, 1 ml</u>	94,596	\$1,183,018	\$12.5060	C H 1%	Access may be widened and/or SA restrictions removed depending on pricing received
<u>Inj 120 mg per 0.8 ml</u>	57,438	\$892,587	\$15.5400	C H 1%	Access may be widened and/or SA restrictions removed depending on pricing received
<u>Inj 150 mg per ml, 1 ml</u>	43,222	\$767,623	\$17.7600	C H 1%	Access may be widened and/or SA restrictions removed depending on pricing received
<b>Eptifibatide</b>					
Inj 0.75 mg per ml, 100 ml				H 1%	
Inj 2 mg per ml, 10 ml				H 1%	
<b>Ferric subsulphate</b>					
Gel 25.9%				H 1%	
Solution 500 ml				H 1%	
<b>Folic Acid</b>					
Inj 5 mg per ml, 10 ml				H 1%	
Tab 0.8 mg	6,094,210	\$120,665	\$0.0198	C H 1%	
Tab 5 mg	5,807,240	\$118,584	\$0.0204	C H 1%	
<b>Fondaparinux sodium</b>					
Inj 2.5 mg syringe				H 1%	
Inj 7.5 mg syringe				H 1%	
<b>Pegfilgrastim</b>					
Inj 6 mg per 0.6 ml prefilled syringe	4,095	\$4,422,600	\$1,080.0000 #	C H 1%	A rebate currently exists. Delisting and/or subsidy reduction and/or price protection until 31/12/2015
<b>Phenindione</b>					
Tab 10 mg				H 1%	
Tab 25 mg				H 1%	
Tab 50 mg				H 1%	
<b>Polidocanol</b>					
Inj 0.5%, 30 ml vial				H 1%	
<b>Potassium chloride</b>					
Tab eff 548 mg (14 m eq) with chloride 285 mg (8 m eq)	292,443	\$25,638	\$0.0877 *	C H 1%	
<u>Tab long-acting 600 mg</u>	8,399,816	\$311,633	\$0.0371	C H 1%	
<b>Potassium dihydrogen phosphate</b>					
Inj 1 mmol per ml, 10 ml				H 1%	
<b>Sodium acetate</b>					
Inj 4 mml per ml, 20 ml ampoule				H 1%	
<b>Sodium chloride</b>					
inj 0.9%, 10 ml, prefilled syringe				H 1%	For use in flushing of in-situ vascular access devices only

sole supply

11  
# = rebate \* = part charge @ = ASP + = patent

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Blood and Blood Forming Organs**

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
<b>Sodium chloride</b>					
inj 0.9%, 3 ml, prefilled syringe				H 1%	For use in flushing of in-situ vascular access devices only
inj 0.9%, 5 ml, prefilled syringe				H 1%	For use in flushing of in-situ vascular access devices only
Oral liq 2 mmol/ml				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
Tab 600 mg				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
<b>Sodium citrate with sodium chloride and potassium chloride</b>					
Inj 4.2 mg with sodium chloride 5.7 mg and potassium chloride 74.6 mcg per ml, 5,000 ml bag				H 1%	
<b>Sodium dihydrogen phosphate</b>					
Inj 1 mmol per ml, 20 ml ampoule				H 1%	
<b>Sodium polystyrene sulphonate</b>					
Powder	238,500	\$47,223	\$0.1980	C H 1%	
<b>Tenecteplase</b>					
Inj 50 mg vial				H 1%	
<b>Thrombin</b>					
Powder				H 1%	
<b>Trisodium citrate</b>					
Inj 4%, 5 ml ampoule				H 1%	
Inj 46.7%, 3 ml syringe				H 1%	
Inj 46.7%, 5 ml ampoule				H 1%	
<b>Urokinase</b>					
Inj 10,000 iu				H 1%	
Inj 100,000 iu				H 1%	
Inj 50,000 iu				H 1%	
Inj 500,000 iu				H 1%	

**Cardiovascular System**

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
<b>Alprostadil</b>					
<u>Inj 0.5 mg per ml, 1 ml</u>				H 1%	
<b>Ambrisentan</b>					
Tab 10 mg	1,440	\$220,080	\$152.8333 #	+ C H 1%	A rebate currently exists. Reference pricing protection until 31/12/2014. Longer transition periods may apply to this product
Tab 5 mg	600	\$91,700	\$152.8333 #	+ C H 1%	A rebate currently exists. Reference pricing protection until 31/12/2014. Longer transition periods may apply to this product
<b>Atenolol</b>					
<u>Tab 50 mg</u>	4,994,987	\$55,544	\$0.0111	C H 1%	
<u>Tab 100 mg</u>	1,979,588	\$36,108	\$0.0182	C H 1%	
<b>Atorvastatin</b>					
<u>Tab 10 mg</u>	17,045,438	\$477,272	\$0.0280	C H 1%	
<u>Tab 20 mg</u>	30,292,982	\$1,403,474	\$0.0463	C H 1%	
<u>Tab 40 mg</u>	30,675,212	\$2,494,815	\$0.0813	C H 1%	
<u>Tab 80 mg</u>	7,904,143	\$1,425,354	\$0.1803	C H 1%	
<b>Bezafibrate</b>					
<u>Tab 200 mg</u>	841,724	\$90,721	\$0.1078	C H 1%	
<u>Tab long-acting 400 mg</u>	4,704,240	\$893,806	\$0.1900	C H 1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Cardiovascular System**

<b>Chemical Name</b>					<b>DV</b>	
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>Limit</b>	<b>Comments</b>
<b>Bosentan</b>						
Tab 125 mg	28,433	\$710,825	\$25.0000 #	C H	1%	A rebate currently exists for one of the listed products. One of the listed products has delisting and/or subsidy reduction and/or price protection until 31/12/2015. Longer transition periods may apply to this product
Tab 62.5 mg	5,547	\$138,675	\$25.0000 #	C H	1%	A rebate currently exists for one of the listed products. One of the listed products has delisting and/or subsidy reduction and/or price protection until 31/12/2015. Longer transition periods may apply to this product
<b>Bumetanide</b>						
Inj 500 mcg per ml, 4 ml				C H	1%	
Tab 1 mg	1,682,005	\$275,176	\$0.1636	C H	1%	
<b>Candesartan</b>						
<u>Tab 4 mg</u>	3,930,522	\$180,372	\$0.0459	C H	1%	
<u>Tab 8 mg</u>	6,982,579	\$473,279	\$0.0678	C H	1%	
<u>Tab 16 mg</u>	6,771,140	\$765,884	\$0.1131	C H	1%	
<u>Tab 32 mg</u>	4,163,872	\$817,035	\$0.1962	C H	1%	
<b>Candesartan with hydrochlorothiazide</b>						
Candesartan 16 mg, hydrochlorothiazide 12.5 mg tablet				C H	1%	Not currently listed on the Pharmaceutical Schedule
Candesartan 8 mg, hydrochlorothiazide 12.5 mg tablet				C H	1%	Not currently listed on the Pharmaceutical Schedule
<b>Celiprolol</b>						
Tab 200 mg	3,789,629	\$400,033	\$0.1056	C H	1%	
<b>Clonidine</b>						
<u>Inj 150 mcg per ml, 1 ml</u>	12,871	\$41,367	\$3.2140	C H	1%	
<u>Tab 25 mcg</u>	3,020,403	\$406,939	\$0.1347	C H	1%	
<u>Tab 150 mcg</u>	559,078	\$191,876	\$0.3432	C H	1%	
<b>Dobutamine</b>						
Inj 12.5 mg per ml, 20 ml				H	1%	
<b>Dopamine</b>						
Inj 40 mg per ml, 5 ml				H	1%	
<b>Enalapril</b>						
Tab 5 mg	3,110,877	\$37,019	\$0.0119	C H	1%	
Tab 10 mg	3,209,473	\$47,179	\$0.0147	C H	1%	
Tab 20 mg	3,425,245	\$65,422	\$0.0191	C H	1%	
<b>Felodipine</b>						
<u>Tab long-acting 2.5 mg</u>	10,793,253	\$1,043,384	\$0.0967	C H	1%	
<u>Tab long-acting 5 mg</u>	16,701,572	\$1,725,773	\$0.1033	C H	1%	
<u>Tab long-acting 10 mg</u>	12,076,370	\$1,851,670	\$0.1533	C H	1%	
<b>Furosemide</b>						
<u>Tab 40 mg</u>	35,431,138	\$363,169	\$0.0103	C H	1%	
<u>Tab 500 mg</u>	285,636	\$142,818	\$0.5000	C H	1%	
<b>Glyceryl trinitrate</b>						
Tab 500 mcg - 600 mcg	103,800	\$8,304	\$0.0800	C H	1%	
Inj 1 mg per ml, 5 ml				H	1%	
Inj 1 mg per ml, 50 ml				H	1%	
<b>Labetalol</b>						
Tab 50 mg	217,590	\$17,908	\$0.0823	C H	1%	
Tab 100 mg	728,706	\$73,308	\$0.1006	C H	1%	
Tab 200 mg	813,310	\$142,736	\$0.1755	C H	1%	
<b>Levosimendan</b>						
Inj 2.5 mg per ml, 10 ml vial				H	1%	

sole supply

13  
#=-rebate \*=part charge @=ASP +=patent

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Cardiovascular System**

<b>Chemical Name</b>						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
<b>Levosimendan</b>						
Inj 2.5 mg per ml, 5 ml vial				H 1%		
<b>Lisinopril</b>						
Tab 5 mg	1,154,281	\$45,917	\$0.0398	C H 1%		
Tab 10 mg	1,339,348	\$60,713	\$0.0453	C H 1%		
Tab 20 mg	1,768,155	\$95,869	\$0.0542	C H 1%		
<b>Milrinone</b>						
Inj 1 mg per ml, 10 ml				H 1%		
<b>Nadolol</b>						
Tab 40 mg	1,974,638	\$307,451	\$0.1557	C H 1%		
Tab 80 mg	558,772	\$132,652	\$0.2374	C H 1%		
<b>Nifedipine</b>						
Cap 5 mg				H 1%		
<b>Propranolol</b>						
Cap long-acting 160 mg	623,797	\$100,182	\$0.1606	C H 1%		
Tab 10 mg	2,977,075	\$108,663	\$0.0365	C H 1%		
Tab 40 mg	2,881,265	\$133,979	\$0.0465	C H 1%		
<b>Quinapril</b>						
Tab 5 mg	8,346,527	\$319,004	\$0.0382	C H 1%		
Tab 10 mg	13,102,613	\$675,571	\$0.0516	C H 1%		
Tab 20 mg	21,795,141	\$1,535,250	\$0.0704	C H 1%		
<b>Quinapril with Hydrochlorothiazide</b>						
Tab 10 mg with hydrochlorothiazide 12.5 mg	2,688,799	\$302,033	\$0.1123	C H 1%		
Tab 20 mg with hydrochlorothiazide 12.5 mg	7,692,804	\$1,171,845	\$0.1523	C H 1%		
<b>Timolol maleate</b>						
Tab 10 mg	95,855	\$10,113	\$0.1055	C H 1%		
<b>Verapamil hydrochloride</b>						
Tab 40 mg	241,410	\$16,923	\$0.0701	C H 1%		
Tab long-acting 120 mg	1,871,888	\$113,811	\$0.0608	C H 1%		
Tab long-acting 240 mg	1,350,651	\$135,065	\$0.1000	C H 1%		

**Dermatologicals**

<b>Chemical Name</b>						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
<b>Adapalene</b>						
Crm 0.1%	269,340	\$205,506	\$0.7630 #	C H 1%	A rebate currently exists	
Gel 0.1%	536,400	\$409,273	\$0.7630 #	C H 1%	A rebate currently exists	
<b>Benzoyl peroxide</b>						
Soln 2.5%				C H 1%	Not currently listed on the Pharmaceutical Schedule	
Soln 5%				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule	
<b>Betamethasone Dipropionate With Calcipotriol</b>						
Gel 500 mcg with calcipotriol 50 mcg per g	536,730	\$467,315	\$0.8707	C H 1%		
Oint 500 mcg with calcipotriol 50 mcg per g	1,735,320	\$1,510,891	\$0.8707	C H 1%		
<b>Betamethasone Valerate</b>						
Crm 0.1%	7,592,050	\$531,444	\$0.0700	C H 1%		
Lotn 0.1%	405,350	\$81,475	\$0.2010	C H 1%		
<b>Betamethasone Valerate with Cloiquinol</b>						
Crm 0.1% with cloiquinol 3%	101,970	\$23,728	\$0.2327 *	C H 1%		
Oint 0.1% with cloiquinol 3%	56,010	\$13,034	\$0.2327 *	C H 1%		
<b>Betamethasone valerate with fusidic acid</b>						
Crm 0.1% with fusidic acid 2%	294,855	\$68,604	\$0.2327 *	C H 1%		

sole supply

14  
#=-rebate \*=part charge @=ASP +=patent

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Dermatologicals**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Calamine</b>						
Lotn, BP - 200 ml or less					H 1%	
Crn, aqueous, BP	1,865,383	\$33,017	\$0.0177		C H 1%	
<u>Lotn, BP</u>	3,637,133	\$24,442	\$0.0067		C H 1%	
<b>Calcipotriol</b>						
Crn 50 mcg per g (pack size 30 g or less)	28,440	\$15,167	\$0.5333		C H 1%	
Crn 50 mcg per g (pack size greater than 30 g)	1,175,600	\$529,020	\$0.4500		C H 1%	
Oint 50 mcg per g (pack size 30 g or less)					C H 1%	
Oint 50 mcg per g (pack size greater than 30 g)	1,275,100	\$573,795	\$0.4500		C H 1%	
Soln 50 mcg per ml (pack size 30 ml or less)	236,910	\$126,351	\$0.5333		C H 1%	
Soln 50 mcg per ml (pack size greater than 30 ml)					C H 1%	
<b>Cetomacrogol</b>						
Crn BP	49,092,990	\$309,286	\$0.0063		C H 1%	
Crn BP [100 g or less]					H 1%	
<b>Chlorhexidine</b>						
Crn 1% obstetric					H 1%	
<b>Chlorhexidine gluconate</b>						
<u>Handrub 0.5% - 1% with ethanol 70%</u>	2,641,001	\$23,188	\$0.0088		C 1%	Chlorhexidine strengths from 0.5% to 1% would be considered
<b>Ciclopirox olamine</b>						
Nail soln 8%	168,854	\$198,522	\$1.1757		C H 1%	
<b>Clobetasone Butyrate</b>						
Crn 0.05% (pack size 30 g or less)				*	H 1%	
Crn 0.05% (pack size greater than 30 g)	839,930	\$135,481	\$0.1613	*	C H 1%	
<b>Crotamiton</b>						
<u>Crn 10%</u>	650,100	\$113,117	\$0.1740		C H 1%	
<b>Dimethicone</b>						
Crn 10% BPC					C H 1%	Not currently listed on the Pharmaceutical Schedule
<b>Fluorouracil sodium</b>						
<u>Crn 5%</u>	1,088,260	\$1,369,031	\$1.2580		C H 1%	Delisting and/or subsidy reduction and/or price protection until 30/06/2015
<b>Hydrocortisone Butyrate</b>						
<u>Lipocream 0.1% (pack size 30 g or less)</u>	958,560	\$73,483	\$0.0767		C H 1%	
<u>Lipocream 0.1% (pack size greater than 30 g)</u>	10,113,600	\$692,782	\$0.0685		C H 1%	
<u>Milky Emulsion 0.1% (pack size greater than 30 g)</u>	1,429,200	\$97,900	\$0.0685		C H 1%	
<u>Oint 0.1% (pack size greater than 30 g)</u>	2,522,500	\$172,791	\$0.0685		C H 1%	
<u>Scalp lotn 0.1%</u>	3,593,226	\$131,153	\$0.0365		C H 1%	
<b>Hydrocortisone with Miconazole</b>						
Crn 1% with miconazole nitrate 2%	5,108,675	\$715,215	\$0.1400		C H 1%	
<b>Hydrocortisone with paraffin and wool fat</b>						
Lotn 1% with paraffin liquid 15.9% and wool fat 0.6%, 100 g					H 1%	
Lotn 1% with paraffin liquid 15.9% and wool fat 0.6%, 15 g					H 1%	
Lotn 1% with paraffin liquid 15.9% and wool fat 0.6%, 500 g					C 1%	Not currently listed in Section B of the Pharmaceutical Schedule
<b>Hydrogen peroxide</b>						
3% (10 vol)					C H 1%	Preference for pack size <200mL
Crn 1%	564,780	\$322,303	\$0.5707 #		C H 1%	A rebate currently exists

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Dermatologicals**

<b>Chemical Name</b>						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
<b>Isotretinoin</b>						
<u>Cap 10 mg</u>	1,413,834	\$220,445	\$0.1559		C H 1%	Information on appropriate use should be available on a website
<u>Cap 20 mg</u>	1,129,531	\$272,127	\$0.2409		C H 1%	Information on appropriate use should be available on a website
<b>Mometasone furoate</b>						
<u>Crm 0.1% (pack size 30 g or less)</u>	200,126	\$23,768	\$0.1188		C H 1%	
<u>Crm 0.1% (pack size greater than 30 g)</u>	2,182,379	\$165,811	\$0.0760		C H 1%	
<u>Oint 0.1% (pack size 30 g or less)</u>	156,123	\$18,542	\$0.1188		C H 1%	
<u>Oint 0.1% (pack size greater than 30 g)</u>	2,187,312	\$166,186	\$0.0760		C H 1%	
<b>Mupirocin</b>						
Oint 2%	1,451,415	\$638,623	\$0.4400	*	C H 1%	Any agreement may be subject to Special Authority restriction
<b>Oil in Water Emulsion</b>						
<u>Crm</u>	92,466,380	\$486,373	\$0.0053		C H 1%	
<b>Paraffin</b>						
White soft or yellow soft (pack size 30 g or less)					H 1%	
<b>Starch</b>						
Powder					C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule

**Genito Urinary System**

<b>Chemical Name</b>						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
<b>Condoms</b>						
51 mm or less (nominal width)	69,153	\$6,417	\$0.0928		C	
52 mm - 54 mm (nominal width)	1,210,844	\$112,366	\$0.0928		C	
55 mm - 58 mm (nominal width)	5,703,891	\$529,321	\$0.0928		C	
59 mm or greater (nominal width)	166,387	\$15,441	\$0.0928		C	
Female condom					C	Not currently listed on the Pharmaceutical Schedule
Flavoured 54 mm or less (nominal width)	683,189	\$63,400	\$0.0928		C	
Flavoured 55 mm or greater (nominal width)					C	
Latex-free 54 mm or less (nominal width)					C	Not currently listed on the Pharmaceutical Schedule
Latex-free 55 mm or greater (nominal width)					C	Not currently listed on the Pharmaceutical Schedule
<b>Medical lubricated jelly</b>						
<200 ml					C	
<b>Norethisterone</b>						
<u>Tab 350 mcg</u>	10,990,140	\$785,026	\$0.0714		C H 1%	
<b>Oestriol</b>						
Crm 1 mg per g with applicator	2,272,245	\$954,686	\$0.4202		C H 1%	
Pessaries 500 mcg	319,116	\$138,911	\$0.4353		C H 1%	
<b>Oxytocin</b>						
<u>Inj 5 iu per ml, 1 ml</u>	1,095	\$1,040	\$0.9500		C H 1%	
<u>Inj 10 iu per ml, 1 ml</u>	4,427	\$5,295	\$1.1960		C H 1%	
<u>Inj 5 iu with ergometrine maleate 500 mcg per ml, 1 ml</u>	3,240	\$7,212	\$2.2260		C H 1%	
<b>Solifenacin succinate</b>						
Tab 5 mg	2,270,758	\$4,276,587	\$1.8833 #		C H 1%	A rebate currently exists
Tab 10 mg	477,214	\$898,751	\$1.8833 #		C H 1%	A rebate currently exists



**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Hormone Preparations - Systemic Excluding Contraceptive Hormones**

<b>Chemical Name</b>						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
<b>Cabergoline</b>						
Tab 0.5 mg	65,123	\$203,509	\$3.1250	C H 1%		
<b>Cyproterone Acetate</b>						
Tab 50 mg	741,828	\$278,927	\$0.3760	C H 1%		
Tab 100 mg	79,341	\$54,349	\$0.6850	C H 1%		
<b>Danazol</b>						
Cap 100 mg	16,148	\$11,034	\$0.6833	C H 1%		
Cap 200 mg	12,034	\$11,773	\$0.9783	C H 1%		
<b>Dexamethasone</b>						
Tab 0.5 mg - 1 mg	491,380	\$28,844	\$0.0587	C H 1%	1 mg tablet units and subsidy shown. A 0.5 mg tablet is not currently listed on the Pharmaceutical Schedule	
Tab 4 mg	901,570	\$73,568	\$0.0816	C H 1%		
<b>Ethinylestradiol</b>						
Tab 10 mcg	282,846	\$49,781	\$0.1760	C H 1%		
<b>Hydrocortisone</b>						
Tab 5 mg	3,108,193	\$251,764	\$0.0810	C H 1%		
Tab 20 mg	129,617	\$26,338	\$0.2032	C H 1%		
<b>Methylprednisolone</b>						
Tab 4 mg	25,464	\$15,278	\$0.6000	C H 1%		
Tab 100 mg	24,109	\$200,727	\$8.3260	C H 1%		
<b>Methylprednisolone Acetate</b>						
Inj 40 mg per ml, 1 ml	3,585	\$24,020	\$6.7000	C H 1%		
<b>Methylprednisolone Acetate with Lignocaine</b>						
Inj 40 mg per ml with lignocaine 1 ml	2,397	\$17,978	\$7.5000	C H 1%		
<b>Methylprednisolone Sodium Succinate</b>						
Inj 40 mg per ml, 1 ml	1,155	\$8,663	\$7.5000	C H 1%		
Inj 62.5 mg per ml, 2 ml	635	\$11,748	\$18.5000	C H 1%		
Inj 500 mg	50	\$900	\$18.0000	C H 1%		
Inj 1 g	173	\$6,488	\$37.5000	C H 1%		
<b>Oestradiol valerate</b>						
Tab 0.5 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule	
Tab 1 mg	1,124,128	\$165,359	\$0.1471	C H 1%		
Tab 2 mg	1,295,766	\$190,607	\$0.1471	C H 1%		
<b>Oestriol</b>						
Tab 2 mg	238,112	\$55,551	\$0.2333	C H 1%		
<b>Prednisolone</b>						
Oral liq 5 mg per ml	3,836,232	\$1,336,275	\$0.3483	C H 1%	Preference for packsize <50 ml	
<b>Terlipressin</b>						
Inj 1 mg				H 1%		
<b>Testosterone</b>						
Transdermal patch 2.5 mg	132,616	\$176,817	\$1.3333	C H 1%		
Transdermal patch 5 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule	
<b>Testosterone undecanoate</b>						
Cap 40 mg	847,862	\$440,464	\$0.5195	C H 1%		
<b>Tetracosactrin</b>						
Inj 250 mcg	204	\$3,614	\$17.7180	C H 1%		
Inj 1 mg per ml, 1 ml	43	\$1,271	\$29.5600	C H 1%		

**Infections**

<b>Chemical Name</b>						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

Infections						
Chemical Name	Units	Cost	Unit Subsidy	DV	Limit	Comments
Line Item						
<b>Aciclovir</b>						
<u>Inj 250 mg</u>				H	1%	
<b>Albendazole</b>						
Tab 200 mg				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule. Any listing may be subject to Special Authority restriction
Tab 400mg	1,280	\$18,126	\$14.1608	C H	1%	
<b>Amoxicillin clavulanate</b>						
<u>Grans for oral liq amoxicillin 125 mg with potassium clavulanate 31.25 mg per 5 ml</u>	6,991,684	\$112,566	\$0.0161	@	C H	1% Additional Stock Pharmaceutical
<u>Grans for oral liq amoxicillin 250 mg with potassium clavulanate 62.5 mg per 5 ml</u>	13,282,803	\$290,893	\$0.0219	@	C H	1% Additional Stock Pharmaceutical
<u>Inj 600 mg</u>				H	1%	
<u>Inj 1.2 g</u>				H	1%	
<b>Amphotericin B</b>						
Inj 50 mg				H	1%	
<u>Liposomal inj 50 mg</u>				H	1%	
<b>Artemether with lumefantrine</b>						
Tab 20 mg with lumefantrine 120 mg				H	1%	
<b>Azithromycin</b>						
Grans for oral liq 200 mg per 5 ml	92,380	\$40,647	\$0.4400	C H	1%	Delisting and/or subsidy reduction and/or price protection until 1/07/2015
Tab 250 mg	36,471	\$12,157	\$0.3333	C H	1%	
<u>Tab 500 mg</u>	145,805	\$91,128	\$0.6250	C H	1%	
<b>Aztreonam</b>						
Inj 1 g				H	1%	
<b>Benzathine Benzylpenicillin</b>						
<u>Inj 1.2 mega u</u>	8,182	\$257,733	\$31.5000	@	C H	1% Additional Stock Pharmaceutical
<b>Caspofungin</b>						
Inj 50 mg				H	1%	
Inj 70 mg				H	1%	
<b>Cefepime Hydrochloride</b>						
Inj 1 g				H	1%	
Inj 2 g				H	1%	
<b>Cefotaxime</b>						
Inj 500 mg				H	1%	
<b>Cefoxitin Sodium</b>						
Inj 1 g	5	\$55	\$11.0000	C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule
<b>Cephalexin Monohydrate</b>						
<u>Grans for oral liq 125 mg per 5 ml</u>	1,379,466	\$117,255	\$0.0850	C H	1%	
<u>Grans for oral liq 250 mg per 5 ml</u>	2,336,669	\$268,717	\$0.1150	C H	1%	
<b>Chloramphenicol</b>						
Inj 1 g				H	1%	
<b>Chloroquine phosphate</b>						
Tab 250 mg				H	1%	
<b>Ciprofloxacin</b>						
Inj 2 mg per ml, 100 ml				H	1%	
Oral liq 100 mg per ml				H	1%	Tender will be awarded for either 50 mg per ml or 100 mg per ml
Oral liq 50 mg per ml				H	1%	Tender will be awarded for either 50 mg per ml or 100 mg per ml
<b>Co-Trimoxazole</b>						
Tab trimethoprim 80 mg and sulphamethoxazole 400 mg	3,570,096	\$149,730	\$0.0419	C H	1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

Infections						
Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments	
Line Item						
<b>Cycloserine</b>						
Cap 250 mg	3,373	\$38,473	\$11.4063	C H	1%	
<b>Daptomycin</b>						
Inj 500 mg vial				H	1%	
Inj 350 mg vial				H	1%	
<b>Demeclocycline</b>						
Cap 150 mg				H	1%	
<b>Doxycycline hydrochloride</b>						
Tab 50 mg	566,490	\$54,763	\$0.0967 *	C H	1%	
<b>Efavirenz</b>						
Tab 50 mg	1,230	\$6,492	\$5.2777 #	C H	1%	A rebate currently exists. Delisting and/or subsidy reduction and/or price protection until 1/07/2015
Tab 200 mg	1,674	\$8,835	\$5.2777 #	C H	1%	A rebate currently exists. Delisting and/or subsidy reduction and/or price protection until 1/07/2015
Tab 600 mg	67,630	\$1,070,786	\$15.8330 #	C H	1%	A rebate currently exists. Delisting and/or subsidy reduction and/or price protection until 1/07/2015
<b>Entecavir</b>						
Tab 0.5 mg	352,507	\$4,700,092	\$13.3333 #	C H	1%	A rebate currently exists
<b>Flucloxacillin</b>						
<u>Grans for oral liq 125 mg per 5 ml</u>	3,865,337	\$96,247	\$0.0249	C H	1%	Bids would be accepted for either the sodium or magnesium salts. Palatability will be considered during evaluation
<u>Grans for oral liq 250 mg per 5 ml</u>	5,718,507	\$185,851	\$0.0325	C H	1%	Bids would be accepted for either the sodium or magnesium salts. Palatability will be considered during evaluation
<b>Flucloxacillin sodium</b>						
<u>Cap 250 mg</u>	1,139,774	\$100,300	\$0.0880	C H	1%	
<u>Cap 500 mg</u>	10,928,933	\$1,617,482	\$0.1480	C H	1%	
<b>Flucytosine</b>						
Cap 500 mg				H	1%	
<b>Foscarnet sodium</b>						
Inj 24 mg per ml, 250 ml				H	1%	
<b>Fusidic Acid</b>						
Tab 250 mg	40,266	\$115,765	\$2.8750	C H	1%	
<b>Gentamicin Sulphate</b>						
<u>Inj 40 mg per ml, 2 ml</u>	7,719	\$5,017	\$0.6500	C H	1%	
<b>Hexamine hippurate</b>						
Tab 1 g	200,813	\$36,950	\$0.1840 *	C H	1%	
<b>Indinavir</b>						
Cap 200 mg				C H	1%	
Cap 400 mg	1,080	\$3,119	\$2.8875	C H	1%	
<b>Isoniazid</b>						
<u>Tab 100 mg</u>	218,092	\$43,618	\$0.2000	C H	1%	
<b>Isoniazid with rifampicin</b>						
Tab 100 mg with rifampicin 150 mg	28,440	\$25,607	\$0.9004	C H	1%	
Tab 150 mg with rifampicin 300 mg	115,674	\$207,716	\$1.7957	C H	1%	
<b>Itraconazole</b>						
Oral liq 10 mg per ml	2,850	\$2,694	\$0.9453	C H	1%	
<b>Ketoconazole</b>						
Tab 200 mg	28,277	\$35,932	\$1.2707	C H	1%	
<b>Lincomycin</b>						
Inj 300 mg per ml, 2 ml				H	1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

Infections						
Chemical Name	Units	Cost	Unit Subsidy	DV	Limit	Comments
Line Item						
<b>Linezolid</b>						
Inj 2 mg per ml, 300 ml				H	1%	
Oral liq 20 mg per ml				H	1%	
Tab 600 mg				H	1%	
<b>Mebendazole</b>						
Oral liq 100 mg per 5 ml	33,994	\$4,940	\$0.1453	*	C H	1%
<b>Nevirapine</b>						
Tab 200 mg	171,510	\$274,244	\$1.5990		C H	1%
<b>Nitrofurantoin</b>						
Oral liq					C H	1% Not currently listed on the Pharmaceutical Schedule
Tab modified release 100 mg					C H	1% Not currently listed on the Pharmaceutical Schedule
Tab 50 mg	1,940,862	\$430,871	\$0.2220		C H	1%
Tab 100 mg	736,220	\$276,082	\$0.3750		C H	1%
<b>Praziquantel</b>						
Tab 600mg	683	\$5,808	\$8.5000		C H	1%
<b>Primaquine phosphate</b>						
Tab 7.5 mg	364	\$761	\$2.0893		C H	1%
<b>Pyrazinamide</b>						
Tab 500 mg	93,395	\$55,103	\$0.5900		C H	1%
<b>Pyrimethamine</b>						
Tab 25 mg	630	\$466	\$0.7390		C H	1%
<b>Quinine dihydrochloride</b>						
Inj 600 mg					H	1% Not currently listed on the Pharmaceutical Schedule
<b>Quinine Sulphate</b>						
Tab 300 mg	1,365,191	\$147,604	\$0.1081		C H	1%
<b>Ritonavir</b>						
Tab 100 mg	142,773	\$206,117	\$1.4437	+	C H	1%
<b>Roxithromycin</b>						
Tab 150 mg	2,589,558	\$387,398	\$0.1496	@	C H	1% Additional Stock Pharmaceutical
Tab 300 mg	1,024,649	\$295,099	\$0.2880	@	C H	1% Additional Stock Pharmaceutical
<b>Sodium stibogluconate</b>						
Inj 100 mg per ml					H	1%
<b>Streptomycin sulphate</b>						
Inj 400 mg per ml, 2.5 ml ampoule					H	1%
<b>Sulphadiazine</b>						
Tab 500 mg					C H	1%
<b>Terbinafine</b>						
Inj 40 mg					C H	1% Not currently listed on the Pharmaceutical Schedule
<b>Tigecycline</b>						
Inj 50 mg vial					H	1%
<b>Tobramycin</b>						
Inj 100 mg per ml, 5 ml vial					C H	1% Not currently listed in Section B of the Pharmaceutical Schedule
<b>Trimethoprim</b>						
Oral liq					C H	1% Not currently listed on the Pharmaceutical Schedule
Tab 100 mg					C H	1% Not currently listed in Section B of the Pharmaceutical Schedule
Tab 300 mg	1,544,775	\$286,710	\$0.1856		C H	1%

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Infections**

<b>Chemical Name</b>					<b>DV</b>	
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>Limit</b>	<b>Comments</b>
<b>Trimethoprim with sulphamethoxazole [Co-trimoxazole]</b>						
Inj 16 mg with sulphamethoxazole 80 mg per ml, 5 ml ampoule					H 1%	
<b>Valaciclovir [current access]</b>						
Tab 250 mg					C H 1%	Not currently listed on the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction
Tab 500 mg	71,275	\$244,046	\$3.4240		C H 1%	
Tab 1000 mg					C H 1%	Not currently listed on the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction
<b>Valaciclovir [no SA restrictions]</b>						
Tab 1000 mg					C H 1%	Not currently listed on the Pharmaceutical Schedule
Tab 250 mg					C H 1%	Not currently listed on the Pharmaceutical Schedule
Tab 500 mg					C H 1%	
<b>Valganciclovir</b>						
Tab 450 mg	31,776	\$1,588,800	\$50.0000	+	C H 1%	Access may be widened depending on price
<b>Voriconazole</b>						
Tab 200 mg	11,138	\$582,756	\$52.3214		C H 1%	Delisting and/or subsidy reduction and/or price protection until 1/07/2015
Tab 50 mg	3,173	\$41,362	\$13.0357		C H 1%	Delisting and/or subsidy reduction and/or price protection until 1/07/2015

**Musculoskeletal System**

<b>Chemical Name</b>					<b>DV</b>	
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>Limit</b>	<b>Comments</b>
<b>Atracurium Besylate</b>						
<u>Inj 10 mg per ml, 2.5 ml</u>					H 1%	
<u>Inj 10 mg per ml, 5 ml</u>					H 1%	
<b>Baclofen</b>						
<u>Inj 0.05 mg per ml</u>					C H 1%	
<u>Inj 2 mg per ml, 5 ml</u>	64	\$13,395	\$209.2900		C H 1%	
Oral liq					C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
<b>Diclofenac sodium</b>						
<u>Tab EC 25 mg</u>	670,736	\$26,829	\$0.0400		C H 1%	
<u>Tab EC 50 mg</u>	4,068,899	\$130,205	\$0.0320		C H 1%	
<u>Tab long-acting 75 mg</u>	19,905,724	\$976,177	\$0.0490		C H 1%	
<u>Tab long-acting 100 mg</u>	2,322,528	\$196,254	\$0.0845		C H 1%	
<b>Etidronate Disodium</b>						
<u>Tab 200 mg</u>	478,003	\$75,524	\$0.1580		C H 1%	
<b>Hydroxychloroquine Sulphate</b>						
<u>Tab 200 mg</u>	3,662,534	\$659,256	\$0.1800		C H 1%	
<b>Ibuprofen</b>						
Inj 5 mg per ml, 2 ml					H 1%	
Tab long-acting 800 mg	10,918,012	\$2,955,178	\$0.2707		C H 1%	
<b>Naproxen</b>						
<u>Tab 250 mg</u>	3,551,610	\$150,943	\$0.0425		C H 1%	
Tab long-acting 750 mg	1,608,506	\$321,701	\$0.2000		C H 1%	
<u>Tab 500 mg</u>	7,500,472	\$667,542	\$0.0890		C H 1%	
Tab long-acting 1,000 mg	1,284,491	\$299,710	\$0.2333		C H 1%	
<b>Pancuronium bromide</b>						
Inj 2 mg per ml, 2 ml					H 1%	

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Musculoskeletal System**

<b>Chemical Name</b>						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
<b>Pyridostigmine bromide</b>						
Tab 60 mg	512,955	\$199,539	\$0.3890		C H 1%	
180 mg modified-release tablet					C H 1%	Not currently listed in the Pharmaceutical Schedule
<b>Rocuronium Bromide</b>						
Inj 10 mg per ml, 5 ml					H 1%	
Inj 10 mg per ml, 5 ml					H 1%	
<b>Tenoxicam</b>						
Inj 20 mg					C H 1%	
<b>Vecuronium</b>						
Inj 4 mg					H 1%	
Inj 10 mg					H 1%	

**Nervous System**

<b>Chemical Name</b>						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
<b>Benzocaine</b>						
Gel 20%					H 1%	
<b>Bupivacaine hydrochloride</b>						
Inj 0.25%, 20 ml					H 1%	
Inj 0.5%, 10 ml					H 1%	
Inj 0.5%, 10 ml sterile pack					H 1%	
Inj 0.5%, 20 ml sterile pack					H 1%	
<b>Buspirone hydrochloride</b>						
Tab 5 mg	317,391	\$88,869	\$0.2800		C H 1%	Special Authority restriction removed 1 August 2013
Tab 10 mg	468,654	\$79,671	\$0.1700		C H 1%	Special Authority restriction removed 1 August 2013
<b>Caffeine</b>						
Tab 100 mg					H 1%	
<b>Clomipramine Hydrochloride</b>						
Tab 10 mg	285,848	\$36,017	\$0.1260		C H 1%	
Tab 25 mg	1,828,641	\$158,726	\$0.0868		C H 1%	
<b>Cyclizine Hydrochloride</b>						
Tab 50 mg	1,202,568	\$70,952	\$0.0590		C H 1%	
<b>Cyclizine lactate</b>						
Inj 50 mg per ml, 1 ml	65,011	\$194,382	\$2.9900		C H 1%	
<b>Dexamphetamine Sulphate</b>						
Tab 5 mg	735,737	\$121,397	\$0.1650		C H 1%	
<b>Domperidone</b>						
Tab 10 mg	10,679,989	\$347,100	\$0.0325		C H 1%	
<b>Entacapone</b>						
Tab 200 mg	725,552	\$347,685	\$0.4792		C H 1%	
<b>Ethyl chloride</b>						
Spray 100%					H 1%	
<b>Etomidate</b>						
Inj 2 mg per ml, 10 ml					H 1%	
<b>Fentanyl</b>						
Inj 50 mcg per ml, 2 ml	189,350	\$85,207	\$0.4500		C H 1%	
Inj 50 mcg per ml, 10 ml	20,848	\$24,538	\$1.1770		C H 1%	
<b>Granisetron</b>						
Inj 1 mg					H 1%	Not currently listed on the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Nervous System**

<b>Chemical Name</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>DV Limit</b>	<b>Comments</b>
<b>Haloperidol Decanoate</b>					
Inj 100 mg per ml, 1 ml	6,387	\$71,407	\$11.1800	C H 1%	
Inj 50 mg per ml, 1 ml	3,964	\$22,508	\$5.6780	C H 1%	
<b>Lidocaine [Lignocaine] Hydrochloride</b>					
Gel 2%				H 1%	Tender is for topical gel, not urethral syringe
Inj 1%, 5 ml	118,859	\$41,601	\$0.3500 *	C H 1%	
Inj 1%, 20 ml	4,320	\$10,368	\$2.4000 *	C H 1%	
<u>Inj 2%, 5 ml</u>	23,132	\$6,384	\$0.2760	C H 1%	
<u>Inj 2%, 20 ml</u>	1,638	\$3,931	\$2.4000	C H 1%	
<b>Lidocaine [lignocaine] hydrochloride with adrenaline</b>					
Inj 1% with adrenaline 1:100,000, 5 ml ampoule				H 1%	
Inj 1% with adrenaline 1:200,000, 20 ml vial				H 1%	Sterile pack preferred
Inj 2% with adrenaline 1:200,000, 20 ml vial				H 1%	Sterile pack preferred
Inj 2% with adrenaline 1:80,000, 1.7 ml dental cartridge				H 1%	
Inj 2% with adrenaline 1:80,000, 1.8 ml dental cartridge				H 1%	
Inj 2% with adrenaline 1:80,000, 2.2 ml dental cartridge				H 1%	
<b>Lidocaine [lignocaine] hydrochloride with phenylephrine hydrochloride</b>					
Nasal spray 5% with phenylephrine hydrochloride 0.5%				H 1%	
<b>Lithium Carbonate</b>					
<u>Tab 250 mg</u>	1,715,055	\$117,653	\$0.0686	C H 1%	
<u>Tab 400 mg</u>	298,915	\$38,351	\$0.1283	C H 1%	
<b>Lorazepam</b>					
Tab 1 mg	5,971,305	\$473,405	\$0.0793	C H 1%	
Tab 2.5 mg	300,028	\$40,474	\$0.1349	C H 1%	
Inj 2 mg per ml, 1 ml				H 1%	
Inj 4 mg per ml, 1 ml				H 1%	
<b>Methadone hydrochloride</b>					
Inj 10 mg per ml, 1 ml	32,160	\$196,176	\$6.1000	C H 1%	
Tab 5 mg	2,283,774	\$422,498	\$0.1850	C H 1%	
<u>Oral liq 1 mg - 2 mg per ml</u>	1,853,408	\$51,432	\$0.0278	C H 1%	Bids for excipient-free products are encouraged
<u>Oral liq 5 mg per ml</u>	21,805,139	\$605,093	\$0.0278	C H 1%	Bids for excipient-free products are encouraged
<u>Oral liq 10 mg per ml</u>	3,854,155	\$126,224	\$0.0328	C H 1%	Bids for excipient-free products are encouraged
<b>Metoclopramide hydrochloride</b>					
Oral liq 5 mg per 5 ml				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
<b>Midazolam</b>					
Inj 1 mg per ml, 5 ml				H 5%	Delisting and/or subsidy reduction and/or price protection until 1/07/2015
Inj 5 mg per ml, 3 ml				H 5%	Delisting and/or subsidy reduction and/or price protection until 1/07/2015
<b>Mirtazapine</b>					
<u>Tab 30 mg</u>	1,310,845	\$383,645	\$0.2927	C H 1%	Consideration would be given to removing prescribing and dispensing restrictions depending on pricing
<u>Tab 45 mg</u>	508,468	\$236,437	\$0.4650	C H 1%	Consideration would be given to removing prescribing and dispensing restrictions depending on pricing

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Nervous System**

<b>Chemical Name</b>						
<b>Line Item</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>		<b>DV Limit</b>	<b>Comments</b>
<b>Moclobemide</b>						
<u>Tab 150 mg</u>	1,087,796	\$178,029	\$0.1637		C H 1%	
<u>Tab 300 mg</u>	305,071	\$90,026	\$0.2951		C H 1%	
<b>Morphine Hydrochloride</b>						
<u>Oral liq 1 mg per ml</u>	6,985,428	\$308,756	\$0.0442		C H 1%	Bids for excipient-free products are encouraged
<u>Oral liq 2 mg per ml</u>	607,562	\$35,299	\$0.0581		C H 1%	Bids for excipient-free products are encouraged
<u>Oral liq 5 mg per ml</u>	808,263	\$59,205	\$0.0733		C H 1%	Bids for excipient-free products are encouraged
<u>Oral liq 10 mg per ml</u>	486,580	\$52,429	\$0.1078		C H 1%	Bids for excipient-free products are encouraged
<b>Oxycodone hydrochloride</b>						
Inj 50 mg per ml	30,168	\$362,016	\$12.0000		C H 1%	
Cap 5 mg	2,860,123	\$404,707	\$0.1415		C H 1%	Bids for products with child-resistant packaging are encouraged
Cap 10 mg	1,267,025	\$353,500	\$0.2790		C H 1%	Bids for products with child-resistant packaging are encouraged
Cap 20 mg	595,194	\$290,752	\$0.4885		C H 1%	Bids for products with child-resistant packaging are encouraged
<u>Inj 10 mg per ml, 1 ml</u>	49,499	\$99,790	\$2.0160		C H 1%	
<u>Inj 10 mg per ml, 2 ml</u>	84,812	\$337,043	\$3.9740		C H 1%	
<u>Tab controlled-release 10 mg</u>	2,101,442	\$709,237	\$0.3375		C H 1%	Bids for products with child-resistant packaging are encouraged
<u>Tab controlled-release 20 mg</u>	1,421,343	\$817,272	\$0.5750		C H 1%	Bids for products with child-resistant packaging are encouraged
<u>Tab controlled-release 40 mg</u>	412,921	\$381,952	\$0.9250		C H 1%	Bids for products with child-resistant packaging are encouraged
<u>Tab controlled-release 80 mg</u>	149,453	\$254,069	\$1.7000		C H 1%	Bids for products with child-resistant packaging are encouraged
<b>Paracetamol</b>						
<u>Suppos 500 mg</u>	113,544	\$47,007	\$0.4140		C H 1%	
<b>Pethidine hydrochloride</b>						
<u>Tab 50 mg</u>	199,675	\$78,871	\$0.3950		C H 1%	Bids for products with child-resistant packaging are encouraged
<u>Tab 100 mg</u>	79,955	\$46,374	\$0.5800		C H 1%	Bids for products with child-resistant packaging are encouraged
<b>Phenobarbitone</b>						
<u>Tab 15 mg</u>	86,065	\$4,820	\$0.0560		C H 1%	
<u>Tab 30 mg</u>	607,973	\$35,262	\$0.0580		C H 1%	
<b>Phenytoin Sodium</b>						
Inj 50 mg per ml, 2 ml	1,080	\$14,956	\$13.8480		C H 1%	
Inj 50 mg per ml, 5 ml	701	\$10,833	\$15.4540		C H 1%	
<b>Pizotifen</b>						
<u>Tab 500 mcg</u>	1,322,226	\$306,889	\$0.2321		C H 1%	
<b>Pregabalin</b>						
Cap 25 mg				+	C H 1%	Not currently listed on the Pharmaceutical Schedule. Any listing would be subject to restriction; nature of restriction may depend on pricing compared to gabapentin
Cap 75 mg				+	C H 1%	Not currently listed on the Pharmaceutical Schedule. Any listing would be subject to restriction; nature of restriction may depend on pricing compared to gabapentin
Cap 150 mg				+	C H 1%	Not currently listed on the Pharmaceutical Schedule. Any listing would be subject to restriction; nature of restriction may depend on pricing compared to gabapentin



**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Nervous System**

<b>Chemical Name</b>							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
<b>Pregabalin</b>							
Cap 300 mg				+	C H 1%	Not currently listed on the Pharmaceutical Schedule. Any listing would be subject to restriction; nature of restriction may depend on pricing compared to gabapentin	
<b>Prilocaine hydrochloride with felypressin</b>							
Inj 3% with felypressin 0.03 iu per ml, 1.8 ml dental cartridge					H 1%		
Inj 3% with felypressin 0.03 iu per ml, 2.2 ml dental cartridge					H 1%		
<b>Sodium valproate</b>							
Inj 400 mg per 4 ml					H 1%		
<b>Tolcapone</b>							
Tab 100 mg	133,912	\$168,996	\$1.2620		C H 1%		
<b>Tropisetron</b>							
Inj 1 mg per ml, 2 ml					H 1%		
Inj 1 mg per ml, 5 ml					H 1%		
<b>Zopiclone</b>							
Tab 7.5 mg (pack size of 30 tablets or less)					H 1%		
Tab 7.5 mg (pack size greater than 30 tablets)	22,915,218	\$545,382	\$0.0238		C H 1%		
<b>Zuclopenthixol hydrochloride</b>							
Tab 2 mg					C H 1%	Not currently listed on the Pharmaceutical Schedule	
Tab 10 mg	117,552	\$36,970	\$0.3145		C H 1%		
Tab 25 mg					C H 1%	Not currently listed on the Pharmaceutical Schedule	
Tab 40 mg					C H 1%	Not currently listed on the Pharmaceutical Schedule	

**Oncology Agents and Immunosuppressants**

<b>Chemical Name</b>							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
<b>Anagrelide hydrochloride</b>							
Cap 0.5 mg	45,636				PCT C H 1%		
<b>Bleomycin Sulphate</b>							
Inj 15,000 iu					PCT H 1%	Preference for products where stability data >48 hours post-compounding	
<b>Bortezomib</b>							
Inj 1 mg			#	+PCT	H 1%	A rebate currently exists	
Inj 3.5 mg			#	+PCT	H 1%	A rebate currently exists	
<b>Carboplatin</b>							
Inj 10 mg per ml, 15 ml					PCT H 1%	Preference for products where stability data >48 hours post-compounding	
Inj 10 mg per ml, 45 ml					PCT H 1%	Preference for products where stability data >48 hours post-compounding	
<b>Crisantaspase</b>							
Inj 10,000					H 1%	Not currently listed on the Pharmaceutical Schedule. Preference for products where stability data >48 hours post-compounding	
<b>Cyclosporin</b>							
Inf 50 mg per ml, 5 ml					H 1%	Not currently listed on the Pharmaceutical Schedule	
<b>Doxorubicin</b>							
Inj 50 mg					PCT H 1%	Preference for products where stability data >48 hours post-compounding	
Inj 200 mg					PCT H 1%	Preference for products where stability data >48 hours post-compounding	

sole supply

25  
#=-rebate \*=-part charge @=ASP +=patent

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Oncology Agents and Immunosuppressants**

<b>Chemical Name</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>DV</b>	<b>Limit</b>	<b>Comments</b>
Line Item						
<b>Epirubicin</b>						
Inj 2 mg per ml, 25 ml				PCT H	1%	Preference for products where stability data >48 hours post-compounding
Inj 2 mg per ml, 50 ml				PCT H	1%	Preference for products where stability data >48 hours post-compounding
Inj 2 mg per ml, 100 ml				PCT H	1%	Preference for products where stability data >48 hours post-compounding
<b>Erlotinib hydrochloride</b>						
Tab 100 mg	4,542	\$171,536	\$37.7667 #	C H	1%	A rebate currently exists
Tab 150 mg	7,241	\$410,324	\$56.6667 #	C H	1%	A rebate currently exists
<b>Etoposide</b>						
Inj 20 mg per ml, 5 ml			\$25.0000	PCT C H	1%	Preference for products where stability data >48 hours post-compounding
Inj 20 mg per ml, 50 ml				PCT H	1%	Preference for products where stability data >48 hours post-compounding. Not currently listed in the Pharmaceutical Schedule
<b>Etoposide phosphate</b>						
Inj 100 mg (of etoposide base)				PCT H	1%	Preference for products where stability data >48 hours post-compounding
Inj 1g (of etoposide base)				PCT H	1%	Preference for products where stability data >48 hours post-compounding. Not currently listed on the Pharmaceutical Schedule
<b>Fludarabine phosphate</b>						
Tab 10 mg				PCT H	1%	
<b>Idarubicin Hydrochloride</b>						
Inj 5 mg				PCT H	1%	Preference for products where stability data >48 hours post-compounding
Inj 10 mg				PCT H	1%	Preference for products where stability data >48 hours post-compounding
<b>Irinotecan</b>						
Inj 20 mg per ml, 2 ml				PCT H	1%	
Inj 20 mg per ml, 5 ml				PCT H	1%	
<b>Letrozole</b>						
Tab 2.5 mg	645,809	\$104,408	\$0.1617	C H	1%	
<b>Liposomal daunorubicin</b>						
Inj 50 mg				PCT H	1%	Not currently listed on the Pharmaceutical Schedule
<b>Megestrol Acetate</b>						
Tab 160 mg	40,519	\$69,624	\$1.7183	C H	1%	
<b>Methotrexate</b>						
Tab 2.5 mg	1,833,979	\$233,521	\$0.1273	PCT C H	1%	
Tab 10 mg	726,686	\$381,510	\$0.5250	PCT C H	1%	
<b>Oxaliplatin</b>						
Inj 50 mg				PCT H	1%	Preference for products where stability data >48 hours post-compounding
Inj 100 mg				PCT H	1%	Preference for products where stability data >48 hours post-compounding
<b>Pegylated liposomal doxorubicin</b>						
Inj 20 mg				PCT H	1%	Not currently listed on the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction
Inj 50 mg				PCT H	1%	Not currently listed on the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction
<b>Sunitinib</b>						
Cap 12.5 mg	11,514	\$952,117	\$82.6921	C H	1%	
Cap 25 mg	5,971	\$987,511	\$165.3846	C H	1%	

sole supply

26  
#=-rebate \*=part charge @=ASP +=patent

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Oncology Agents and Immunosuppressants**

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
<b>Sunitinib</b>					
Cap 50 mg	7,757	\$2,565,777	\$330.7693	C H 1%	
<b>Topotecan</b>					
Inj 1 mg				H 1%	Not currently listed on the Pharmaceutical Schedule
Inj 4 mg				H 1%	Not currently listed on the Pharmaceutical Schedule
<b>Vinorelbine</b>					
Inj 10 mg per ml, 1 ml				PCT H 1%	Sole supply ends 30/06/2015. Preference for products where stability data >48 hours post-compounding
Inj 10 mg per ml, 5 ml				PCT H 1%	Sole supply ends 30/06/2015. Preference for products where stability data >48 hours post-compounding

**Respiratory System and Allergies**

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
<b>Beclomethasone Dipropionate</b>					
Metered aqueous nasal spray, 50 mcg per dose	5,617,400	\$66,004	\$0.0118 *	C H 1%	
Metered aqueous nasal spray, 100 mcg per dose	17,331,800	\$213,181	\$0.0123 *	C H 1%	
<b>Budesonide</b>					
Metered aqueous nasal spray, 50 mcg per dose	2,893,200	\$33,995	\$0.0118 *	C H 1%	
Metered aqueous nasal spray, 100 mcg per dose	17,431,400	\$227,480	\$0.0131 *	C H 1%	
<b>Fluticasone propionate</b>					
<u>Metered aqueous nasal spray, 50 mcg per dose</u>	59,701,200	\$1,144,472	\$0.0192	C H 1%	
<b>Promethazine Hydrochloride</b>					
<u>Oral liq 5 mg per 5 ml</u>	4,195,370	\$117,051	\$0.0279	C H 1%	
<u>Tab 10 mg</u>	1,708,207	\$67,987	\$0.0398	C H 1%	
<u>Tab 25 mg</u>	2,039,822	\$121,981	\$0.0598	C H 1%	
<b>Salbutamol</b>					
<u>Nebuliser soln, 1 mg per ml, 2.5 ml</u>	312,727	\$50,818	\$0.1625	C H 1%	
<u>Nebuliser soln, 2 mg per ml, 2.5 ml</u>	710,354	\$122,181	\$0.1720	C H 1%	
<b>Salbutamol with Ipratropium Bromide</b>					
<u>Nebuliser soln, 2.5 mg with ipratropium bromide 0.5 mg per vial, 2.5 ml</u>	587,914	\$110,234	\$0.1875	C H 1%	

**Sensory Organs**

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
<b>Acetazolamide</b>					
Inj 500mg				H 1%	
<b>Acetic acid with propylene glycol</b>					
Ear drops 2.3% with propylene glycol 2.8%				C H 1%	
<b>Acetylcholine chloride</b>					
Inj 20mg vial with diluent				H 1%	
<b>Bimatoprost</b>					
Eye Drops 0.03%	254,145	\$1,567,228	\$6.1667 #	C H 1%	A rebate currently exists. Delisting and/or subsidy reduction and/or price protection until 30/7/2015. This would exclude the preservative-free market. Unit subsidy expressed as "per ml"

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Sensory Organs**

<b>Chemical Name</b>						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
<b>Brimonidine Tartrate with Timolol Maleate</b>						
Eye drops 0.2% with timolol maleate 0.5%	204,985	\$758,445	\$3.7000 #	C H 1%	A rebate currently exists. Unit subsidy expressed as "per ml"	
<b>Chloramphenicol</b>						
Ear drops 0.5%	26,185			C H 1%	Single dose presentation would not be a DV Pharmaceutical. Not currently listed in Section B of the Pharmaceutical Schedule. Units indicated are for the year ending 30 June 2013	
Eye drops 0.5%, single dose				H 1%		
<u>Eye drops 0.5%</u>	1,596,420	\$191,570	\$0.1200	C H 1%	Single dose presentation would not be a DV Pharmaceutical. Unit subsidy expressed as "per ml"	
<u>Eye oint 1%</u>	582,996	\$402,267	\$0.6900	C H 1%		
<b>Fluorometholone</b>						
<u>Eye drops 0.1%</u>	79,485	\$60,409	\$0.7600	C H 1%	Unit subsidy expressed as "per ml"	
<b>Fusidic Acid</b>						
Eye drops 1%	343,225	\$308,903	\$0.9000	C H 1%	Delisting and/or subsidy reduction and/or price protection until 30/06/2015	
<b>Latanoprost</b>						
<u>Eye drops 50 mcg per ml</u>	710,075	\$565,220	\$0.7960	C H 1%	Unit subsidy expressed as "per ml". This would exclude the preservative-free market	
<b>Mixed salt solution for eye irrigation</b>						
Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium acetate 0.17%, 15 ml				H 1%	Not currently listed on the Pharmaceutical Schedule	
Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium acetate 0.17%, 250 ml				H 1%	Not currently listed on the Pharmaceutical Schedule	
Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, sodium acetate 0.39%, sodium chloride 0.64% and sodium acetate 0.17%, 500 ml				H 1%	Not currently listed on the Pharmaceutical Schedule	
<b>Sodium hyaluronate</b>						
Ophthalmic inj 14 mg per ml				H 1%	Not currently listed on the Pharmaceutical Schedule	
Ophthalmic soln 10 mg per ml				H 1%	Not currently listed on the Pharmaceutical Schedule	

**Various**

<b>Chemical Name</b>						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
<b>Acetylcysteine</b>						
<u>Inj 200 mg per ml, 10 ml</u>	51	\$908	\$17.8000	C H 1%	Minimal usage in the community	
Inj 200 mg per ml, 30 ml	8	\$438	\$54.7500	C H 1%		
<b>Chlorhexidine</b>						
Soln 4%				H 1%		
Soln 5%				H 1%		
<b>Chlorhexidine with cetrimide</b>						
Crm 0.1% with cetrimide 0.5%				H 1%		
Foaming soln 0.5% with cetrimide 0.5%				H 1%		
<b>Chlorhexidine with ethanol</b>						
Soln 0.5% with ethanol 70%, non-staining (pink) 100 ml				H 1%		
Soln 0.5% with ethanol 70%, non-staining (pink) 25 ml				H 1%		

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Various**

<b>Chemical Name</b>	<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>DV Limit</b>	<b>Comments</b>
<b>Chlorhexidine with ethanol</b>					
Soln 0.5% with ethanol 70%, non-staining (pink) 500 ml				H 1%	
Soln 0.5% with ethanol 70%, staining (red) 100 ml				H 1%	
Soln 0.5% with ethanol 70%, staining (red) 500 ml				H 1%	
Soln 2% with ethanol 70%, non-staining (pink) 100 ml				H 1%	
Soln 2% with ethanol 70%, staining (red) 100 ml				H 1%	
Soln 2% with ethanol 70%, staining (red) 500 ml				H 1%	
<b>DEHP-free IV infusion bag</b>					
1,000 ml				H 1%	Not currently listed on the Pharmaceutical Schedule
250 ml				H 1%	Not currently listed on the Pharmaceutical Schedule
3,000 ml				H 1%	Should have at least three lead transfer sets attached. Not currently listed on the Pharmaceutical Schedule
500 ml				H 1%	Not currently listed on the Pharmaceutical Schedule
<b>Desferrioxamine Mesylate</b>					
Inj 500 mg	11,138	\$110,266	\$9.9000	C H 1%	
<b>Flumazenil</b>					
Inj 0.1 mg per ml, 5 ml				H 1%	
<b>Iodine with ethanol</b>					
Soln with ethanol 70%, 100 ml				H 1%	
<b>Isopropyl alcohol</b>					
Soln 70%, 500 ml				H 1%	
<b>latex free IV infusion bag</b>					
1,000 ml				H 1%	Not currently listed on the Pharmaceutical Schedule
250 ml				H 1%	Not currently listed on the Pharmaceutical Schedule
3,000 ml				H 1%	Should have at least three lead transfer sets attached. Not currently listed on the Pharmaceutical Schedule
500 ml				H 1%	Not currently listed on the Pharmaceutical Schedule
<b>Naloxone Hydrochloride</b>					
Inj 400 mcg per ml, 1 ml	9,110	\$60,126	\$6.6000	C H 1%	
<b>Povidone Iodine</b>					
Oint 10%			#	H 1%	A rebate currently exists
Pad 10%				H 1%	
Soln 10%			#	H 1%	A rebate currently exists
Soln 5%				H 1%	
Soln 7.5%				H 1%	
Swab set 10%				H 1%	
<b>Povidone Iodine with ethanol</b>					
Soln 10% with ethanol 30%				H 1%	
Soln 10% with ethanol 70%				H 1%	
<b>PVC-free IV infusion bag</b>					
1,000 ml				H 1%	Not currently listed on the Pharmaceutical Schedule
250 ml				H 1%	Not currently listed on the Pharmaceutical Schedule

**SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)**

**Various**

<b>Chemical Name</b>		<b>Units</b>	<b>Cost</b>	<b>Unit Subsidy</b>	<b>DV Limit</b>	<b>Comments</b>
Line Item						
<b>PVC-free IV infusion bag</b>						
	3,000 ml				H 1%	Should have at least three lead transfer sets attached. Not currently listed on the Pharmaceutical Schedule
	500 ml				H 1%	Not currently listed on the Pharmaceutical Schedule
<b>PVC-free, DEHP-free and latex free IV infusion bag</b>						
	1,000 ml				H 1%	Not currently listed on the Pharmaceutical Schedule
	250 ml				H 1%	Not currently listed on the Pharmaceutical Schedule
	3,000 ml				H 1%	Should have at least three lead transfer sets attached. Not currently listed on the Pharmaceutical Schedule
	500 ml				H 1%	Not currently listed on the Pharmaceutical Schedule
<b>Sodium Hypochlorite</b>						
	Soln				H 1%	